Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: Study protocol for a randomized controlled trial

Trials

Volumn 17, Issue 1, 2016, Pages

  Yan, Meihua ^a   Wen, Yumin ^a   Yang, Liping ^b   Wu, Xi'ai ^a   Lu, Xiaoguang ^b   Zhang, Bingxuan ^a   Huang, Weiping ^c   Li, Ping ^a  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^c Beijing Qihuang Drug Clinical Research Center   (China)

Author keywords

Chinese herbal medicine; Diabetic kidney disease; Macroalbuminuria; Randomized controlled trial; Tangshen Formula

Indexed keywords

ANTIDIABETIC AGENT; ASTRAGALUS MEMBRANACEUS EXTRACT; CORNUS OFFICINALIS EXTRACT; EUONYMUS ALATUS EXTRACT; IRBESARTAN; PANAX NOTOGINSENG EXTRACT; PLACEBO; PLANT EXTRACT; REHMANNIA GLUTINOSA EXTRACT; RHEUM PALMATUM EXTRACT; SOUR ORANGE EXTRACT; TANGSHEN EXTRACT; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CREATININE; HERBACEOUS AGENT; TANGSHEN;

ADULT; AGED; ARTICLE; ASTRAGALUS MEMBRANACEUS; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CORNUS OFFICINALIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ISOLATION; DRUG SAFETY; EUONYMUS ALATUS; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MEDICINAL PLANT; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANAX NOTOGINSENG; PLANT ROOT; PROTEIN URINE LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REHMANNIA GLUTINOSA; RHUBARB; SOUR ORANGE; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT OUTCOME; ALBUMINURIA; BLOOD; CHINA; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPLICATION; DIABETIC NEPHROPATHY; DRUG EFFECTS; KIDNEY; METHODOLOGY; PATHOPHYSIOLOGY; TIME FACTOR;

ALBUMINURIA; BIOMARKERS; CHINA; CLINICAL PROTOCOLS; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84969540890     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-016-1385-2     Document Type: Article

References (31)

1. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864-83. doi: 10.2337/dc14-1296.
2. Ruggenenti P, Remuzzi G. Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment? Nephrol Dial Transplant. 2000;15(12):1900-2.
3. American Diabetes Association. 9. Microvascular complications and foot care. Diabetes Care. 2016;39 Suppl 1:S72-80. doi: 10.2337/dc16-S012.
4. Cheng X, Nayyar S, Wang M, Li X, Sun Y, Huang W, et al. Mortality rates among prevalent hemodialysis patients in Beijing: a comparison with USRDS data. Nephrol Dial Transplant. 2013;28(3):724-32. doi: 10.1093/ndt/gfs326.
5. Nakai S, Hanafusa N, Masakane I, Taniguchi M, Hamano T, Shoji T, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2012). Ther Apher Dial. 2014;18(6):535-602. doi: 10.1111/1744-9987.12281.
6. Mehrotra R, Chiu YW, Kalantar-Zadeh K, Bargman J, Vonesh E. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med. 2011;171(2):110-8. doi: 10.1001/archinternmed.2010.352.
7. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-39. doi: 10.1056/NEJMoa0808431.
8. Vupputuri S, Kimes TM, Calloway MO, Christian JB, Bruhn D, Martin AA, et al. The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. J Diabetes Complications. 2014;28(1):10-6. doi: 10.1016/j.jdiacomp.2013.09.014.
9. Montoro de Francisco A, Garcia-Luque A, Fernandez M, Puerro M. Side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: are we facing a new syndrome. Am J Cardiol. 2012;110(10):1552-3. doi: 10.1016/j.amjcard.2012.08.027.
10. Roberts JR, Lee JJ, Marthers DA. Angiotensin-converting enzyme (ACE) inhibitor angioedema: the silent epidemic. Am J Cardiol. 2012;109(5):774-5. doi: 10.1016/j.amjcard.2011.11.014.
11. Zhao XF, Su SJ, Yun G, Guo YH, Wang S. Mortality and recurrence of vascular disease among stroke patients treated with combined TCM therapy. J Tradit Chin Med. 2012;32(2):173-8.
12. Ji L, Tong X, Wang H, Tian H, Zhou H, Zhang L, et al. Efficacy and safety of traditional Chinese medicine for diabetes: a double-blind, randomised, controlled trial. PLoS One. 2013;8(2):e56703. doi: 10.1371/journal.pone.0056703.
13. Chen G, Wu X, Yang L, Yang X, Yan M, Li P. Using the Delphi method to survey clinical experts on the characteristics of traditional Chinese symptoms of diabetic nephropathy. China J Trad Chin Med Pharm. 2011;26:2241-4. Chinese.
14. Yang S, Wang Y, Chen Z, Lv J, Wang X, Hu C, et al. Common Chinese medicine syndromes of diabetic nephropathy questionnaire-based study of experts. Chin J Integr Trad West Nephrol. 2013;14:1097-9. Chinese.
15. Zhou D, Zhao J, Mou X, Liu W, Zhou D, Liu Y, et al. Distribution of syndrome stages of diabetic nephropathy. J Beijing Univ Tradit Chin Medi Chin Med Clin Edition. 2012;19(1):38-41. Chinese.
16. Yang L, Li P, Du J, Li J, Deng D, Zhan Y. Canonical correlation analysis of traditional Chinese syndrome and laboratory parameters in 350 patients with diabetic nephropathy. China J Tradit Chin Med Pharm. 2010;25:686-9. Chinese.
17. Zhang H, Li P, Burczynski FJ, Gong Y, Choy P, Sha H, et al. Attenuation of diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with a combination of Chinese herbs (Tangshen Formula). Evid Based Complement Alternat Med. 2011;2011:613737. doi: 10.1155/2011/613737.
18. Zhang H, Li P, Zhao J, Zhao S, Yan M, Luo Y. Effect of Tangshen Formula on expression of TGF-β1 and MMP-9 of renal tissue in STZ-induced diabetic nephropathy rats. Chin J Integr Trad West Nephrol. 2009;10:290-4. Chinese.
19. Guo J, Li P, Wan F, Zhao T, Dong X, Li X, et al. Protective effect of Tangshen Formula on renal function and IL-10, TNF-α, and DA in OLETF rats. Chin J Integr Trad West Nephrol. 2011;12(12):1044-7.
20. Zhu C, Huang M, Liang Q, Wang Y, Hu P, Li P, et al. Effects of Tangshen Formula on phospholipids metabolism in spontaneous Type 2 Diabetic rats. Chem J Chin Univ. 2011;32(7):1512-8. Chinese.
21. Li P, Chen Y, Liu J, Hong J, Deng Y, Yang F, et al. Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial. PLoS One. 2015;10(5):e0126027. doi: 10.1371/journal.pone.0126027.
22. American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care. 2013;36 Suppl 1:S11-66. doi: 10.2337/dc13-S011.
23. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850-86. doi: 10.1053/j.ajkd.2012.07.005.
24. Zheng X. Clinical research guideline of new investigational drug in traditional Chinese medicine. Beijing: China Medical Science Press; 2002.
25. Levey AS, Stevens LA, Schmid CH, Zhang YL. Castro 3rd AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.
26. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806-15. doi: 10.1038/clpt.2011.58.
27. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323-30.
28. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55-68. doi: 10.2165/00002018-200932010-00005.
29. World Health Organization. World Health Organization Collaborating Centre for International Drug Monitoring; Uppsala Monitoring Centre. http://www.who-umc.org. Accessed 26 Apr 2016.
30. He J, Du L, Liu G, Fu J, He X, Yu J, et al. Quality assessment of reporting of randomization, allocation concealment, and blinding in traditional Chinese medicine RCTs: a review of 3159 RCTs identified from 260 systematic reviews. Trials. 2011;12:122. doi: 10.1186/1745-6215-12-122.
31. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, et al. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med. 2006;144(5):364-7.